Our research interests include metabolism, the digestive tract, the central nervous system and the respiratory tract. We investigate manifestations of inflammatory and oncological disease with the goal of better understanding the causes of disease and thus discovering new therapeutic options. We are also dedicated to the detailed investigation of established drugs in order to expand their potential applications and reduce adverse effects.
Our young international team investigates the role of the immune system in tumor diseases, for example lung cancer. Advanced development of immune-based drugs for oncological disease requires the detailed exploration of the immunological environment in the tumor, especially the presence of immunostimulant or immunoinhibitory factors, whose targeted manipulation has recently led to unexpected therapeutic success.
We attempt to decode the molecular basis of myeloid leukemias, especially the pathological changes in RAS oncogenes that are often found with mutations in patients with myeloid leukemia. Employing molecular and cytological methods, disease models and patient specimens, we attempt to make use of our findings in new therapeutic approaches.
Our lab explores new anti-inflammatory therapies for immunological diseases of the lungs and the vascular system. We investigate the mechanisms for how leukocytes enter inflamed tissue and their activation and attempt to identify new targets for active substances.
Our research group analyzes the function of eosinophil granulocytes, a subtype of white blood cells that play an important role in allergies and asthma. Through pharmacological inhibition of these cells, we hope to obtain an effective therapy for a variety of diseases.
Our multidisciplinary group works on the complex communication pathways between the gut microbiome and the brain that are relevant for digestion, brain function and pathological behavioural changes. In addition, we investigate the influence of genetic and environmental factors on behaviour and neurobiology to uncover novel therapeutic targets for neuropsychiatric disease.
We research the effects of high-density lipoproteins (HDL) on inflammatory reactions and how they interact with immune cells and the endothelium of the blood vessels. Looking at a large number of human diseases, we investigate the role played by the modified anti-inflammatory function of HDL in disease development and therapy.
Our lab is concerned with the role of factors that modulate inflammation in inflammatory bowl disease and how an inflamed mucous membrane with its large number of immune cells and their mediators is involved in the development of cancer. The pharmacological manipulation of these factors might significantly influence the origin of tumors and could be used therapeutically.
